Seasonal Influenza Vaccine
Inactivated, Injectible

Manufacturer CSL Biotherapies/Merck & Co. Inc.

Brand Name **Afluria®**

Age **9 years of age and older**

Dose/Presentation 0.5 ml prefilled single dose syringe (thimerosal mercury content = 0 mcg)
5ml multi-dose vial - ten 0.5 mL doses (contains 24.5 mcg of mercury/dose)

Storage Refrigerate immediately. Store at 2º-8º C (35º-46º F). **Do not Freeze.**

Injection Site Deltoid, upper arm.

Route Intramuscular (IM)

Needle Size 22 to 25 gauge, ⅞ to 1¼ inches

Administration May be administered simultaneously or at any interval between doses with inactivated or live antigen.

Schedule for Afluria® vaccination

Age	Dose	Number of Doses	Route and Site
9 years and older	0.5 ml	1	Intramuscular (IM) in deltoid muscle

Afluria® is approved by FDA for the use in persons aged 5 years and older in the U.S. However, ACIP recommends that Afluria® not be administered to children aged 6 months through 8 years of age because of an increased frequency of febrile seizures reported among children of this age group. The febrile seizures were noted mostly among children less than 5 yrs of age. Therefore, children 6 months-8 yrs of age should receive another age appropriate licensed seasonal influenza vaccine formation. If no other formulation is available, providers should discuss the benefits and risks of the influenza vaccination with the parent or the caregiver prior to administering the vaccine to a child 5 - 8 years of age who has a medical condition that increases their risk for influenza complications.
Vaccination efforts should begin as soon as seasonal influenza vaccine is available and continue through the influenza season

Contraindications to Influenza vaccination:

1. Persons with a severe allergic reaction to a previous dose of influenza vaccine
2. Refer to a physician with expertise in management of allergic conditions for further evaluation if following a influenza vaccine the person had immediately cardiovascular changes, respiratory distress, GI, reaction requiring epinephrine or emergency medical attention.**
3. Persons known to have anaphylactic hypersensitivity to eggs, polymyxin, or neomycin.
4. Persons with acute febrile illness, until their symptoms have abated

Precautions:

1. Persons who developed Guillian-Barre′ (GBS) within 6 weeks of a previous influenza vaccination
2. Increased post marketing reports of Afluria® noted an increase of fever and febrile seizures in children, predominantly in children less than 5 yrs of age during the 2010 Southern Hemisphere influenza season.
3. Data supporting the safety and effectiveness in pregnant and nursing women, geriatric and use for < 5yrs olds is not established.

Report all adverse reactions to influenza vaccine to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800) 822-7967

Medical Director's Signature: _____ Effective Date: _____

Reference:
MMWR 8/ 17, 2012 / Vol. 61 / No. 32; 613-618 **http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w**
Drug Insert: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM263239.pdf
CDC Influenza website http://www.cdc.gov/flu
KDHE Influenza website http://www.kdheks.gov/flu/index.html*